INBODY CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28,300 KRW | +0.18% |
|
+2.17% | +11.64% |
| 2023 | InBody Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| 2022 | InBody Releases BPBIO 220 and BPBIO 250 | CI |
| Sales 2024 * | 197B 144M | Sales 2025 * | 222B 162M | Capitalization | 369B 268M |
|---|---|---|---|---|---|
| Net income 2024 * | 41B 29.85M | Net income 2025 * | 48B 34.94M | EV / Sales 2024 * | 1.87 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.66 x |
| P/E ratio 2024 * |
9.43
x | P/E ratio 2025 * |
8.07
x | Employees | 275 |
| Yield 2024 * |
1.15% | Yield 2025 * |
1.15% | Free-Float | 66.51% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.18% | ||
| 1 week | +2.17% | ||
| Current month | -6.14% | ||
| 1 month | -2.75% | ||
| 3 months | +5.01% | ||
| 6 months | +30.41% | ||
| Current year | +11.64% |
1 week
27 050.00
29 400.00
1 month
26 400.0030 700.00
Current year
24 650.0030 700.00
1 year
21 150.0031 250.00
3 years
17 800.0032 850.00
5 years
13 350.0032 850.00
10 years
10 800.0059 600.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ra-Mi Lee
CEO | Chief Executive Officer | 48 | - |
Ki-Chul Cha
FOU | Founder | 66 | 96-05-14 |
Woo-Seong Bang
BRD | Director/Board Member | 45 | 19-03-07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Young-Pil Park
BRD | Director/Board Member | 76 | - |
Ki-Chul Cha
FOU | Founder | 66 | 96-05-14 |
Chang-Heon Woo
BRD | Director/Board Member | 57 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 28,300 | +0.18% | 74 617 |
| 24-04-22 | 28,250 | -1.74% | 25,301 |
| 24-04-19 | 28,750 | +4.36% | 90,992 |
| 24-04-18 | 27,550 | +1.47% | 16,015 |
| 24-04-17 | 27,150 | -0.18% | 7,311 |
End-of-day quote Korea S.E., April 22, 2024
More quotes
InBody Co., Ltd., formerly Biospace Co., Ltd., is a Korea-based company engaged in the manufacture of electronic medical devices. The Company mainly produces body composition analyzers under the brand names of InBody and LookinâBody. The Company mainly produces body composition analyzers under the brand name InBody and LookinâBody. Its InBody series products include InBody720, InBody520, InBody230, InBody R20, InBody S20, InBody S10 and InBody J10. Its Lookin' series products include LookinâBody3.0 and LookinâBody Basic, which are used for measuring proteins, minerals, fats, moistures and others. It also provides body mass index (BMI) measuring devices under the brand name of BSM. The Company distributes its products within domestic market and to overseas markets.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
28,300
KRW
Average target price
38,000
KRW
Spread / Average Target
+34.28%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +11.64% | 267M | |
| +8.52% | 209B | |
| +9.33% | 175B | |
| +12.51% | 131B | |
| +18.94% | 99.98B | |
| -0.84% | 61.12B | |
| +15.02% | 52.34B | |
| -2.10% | 46.5B | |
| +0.17% | 39.24B | |
| +11.50% | 38.47B |
- Stock Market
- Equities
- A041830 Stock
